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ABSTRACT
OBJECTIVE: To analyze the access and utilization profile of biological 
medications for psoriasis provided by the judicial system in Brazil.
METHODS: This is a cross-sectional study. We interviewed a total of 203 patients 
with psoriasis who were on biological medications obtained by the judicial system 
of the State of Sao Paulo, from 2004 to 2010. Sociodemographics, medical, and 
political-administrative characteristics were complemented with data obtained 
from dispensation orders that included biological medications to treat psoriasis 
and the legal actions involved. The data was analyzed using an electronic data 
base and shown as simple variable frequencies. The prescriptions contained in 
the lawsuits were analyzed according to legal provisions.
RESULTS: A total of 190 lawsuits requesting several biological drugs 
(adalimumab, efalizumab, etanercept, and infliximab) were analyzed. Patients 
obtained these medications as a result of injunctions (59.5%) or without having 
ever demanded biological medication from any health institution (86.2%), 
i.e., public or private health services. They used the prerogative of free legal 
aid (72.6%), even though they were represented by private lawyers (91.1%) 
and treated in private facilities (69.5%). Most of the patients used a biological 
medication for more than 13 months (66.0%), and some patients were undergoing 
treatment with this medication when interviewed (44.9%). Approximately one 
third of the patients discontinued treatment due to worsening of their illness 
(26.6%), adverse drug reactions (20.5%), lack of efficacy, or because the doctor 
discontinued this medication (13.8%). None of the analyzed medical prescriptions 
matched the legal prescribing requirements. Clinical monitoring results showed 
that 70.3% of the patients had not undergone laboratory examinations (blood 
work, liver and kidney function tests) for treatment control purposes.
CONCLUSIONS: The plaintiffs resorted to legal action to get access to 
biological medications because they were either unaware or had difficulty 
in accessing them through institutional public health system procedures. 
Access by means of legal action facilitated long-term use of this type of 
medication through irregular prescriptions and led to a high rate of adverse 
drug reactions as well as inappropriate clinical monitoring.
DESCRIPTORS: Psoriasis. Antibodies, Monoclonal, therapeutic 
use. Pharmaceutical Services, legislation & jurisprudence. Judicial 
Decisions. Equity in Access.
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Psoriasis (PSO) is a recurrent, inflammatory, genetic, 
and chronic disease characterized by epidermal prolif-
eration and inflammation. This disease causes scaly 
and erythematous lesions that target the skin, nails, and 
joints. The prevalence rates vary between 0.6% and 
4.8% and equally affect men and women of all races.a
Despite showing benign progression, worsening of the 
conditions causes significant physical and psychological 
RESUMO
OBJETIVO: Analisar o acesso e o perfil de utilização, por via judicial, de 
medicamentos biológicos para o tratamento de psoríase.
MÉTODOS: Estudo transversal descritivo. Foram entrevistados 203 pacientes 
com psoríase que demandaram medicamentos biológicos, por via judicial, ao 
Estado de São Paulo, entre 2004 e 2010. Informações sobre características 
sociodemográficas, médico-sanitárias e político-administrativas foram 
complementadas com dados obtidos das respectivas ordens de dispensação 
quanto a medicamento biológico para tratamento de psoríase e autos 
correspondentes. Os dados foram analisados em banco eletrônico e as variáveis 
sumarizadas por frequência simples. As prescrições contidas nos processos 
foram analisadas quanto aos preceitos legais contidos na lei.
RESULTADOS: Foram analisados 190 autos referentes aos medicamentos 
biológicos: adalimumabe, efalizumabe, etanercepte e infliximabe. Os proponentes 
obtiveram o medicamento por mandado de segurança (59,5%), sem nunca ter 
solicitado o medicamento biológico para outra instituição (86,2%), por sistema de 
saúde público ou privado. Utilizaram-se da prerrogativa de gratuidade de justiça 
(72,6%), embora fossem representados por advogado particular (91,1%) e atendidos 
em consultórios médicos privados (69,5%). Utilizaram o medicamento biológico 
por período > 13 meses (66,0%) e 44,9% faziam uso do medicamento no momento 
da entrevista. Quase um terço daqueles que deixaram de usar os medicamentos 
abandonou o tratamento por piora do quadro (26,6%), efeitos adversos (20,5%), 
falta de eficácia ou suspensão pelo médico (13,8%). Nenhuma prescrição médica 
atendeu aos preceitos legais; 70,3% dos pacientes não haviam realizado exames 
laboratoriais (hemograma, função hepática e renal) para controle do tratamento.
CONCLUSÕES: Os demandantes recorreram à via judicial para obtenção de 
medicamentos biológicos por desconhecimento ou por dificuldades de acesso pelas 
vias institucionais do sistema público de saúde O acesso facilitado pela via judicial 
favorece o uso do medicamento por tempo prolongado por meio de prescrições não 
conformes, frequência elevada de efeitos adversos e monitoramento clínico inadequado.
DESCRITORES: Psoríase. Anticorpos Monoclonais, uso terapêutico. 
Assistência Farmacêutica, legislação & jurisprudência. Decisões 
Judiciais. Equidade no Acesso.
INTRODUCTION
morbidity and has a major impact on the patient’s quality 
of life. The treatment is based on the criteria of the 
Psoriasis Area Severity Index (PASI) and in the impact 
on the quality of life with respect to disease remission 
or increase in the period free of skin lesions.b
According to the national therapeutic guidelinesc and inter-
national guidelines, the treatment of moderate to severe 
PSO should begin with phototherapy.16,a,b In case of failure, 
a Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults: a national clinical 
guideline. Edinburgh: SIGN; 2010 [cited 2014 Mar 31]. Available from: http://www.sign.ac.uk/pdf/sign121.pdf
b National Institute for Health and Clinical Excellence. Psoriasis: the assessment and management of psoriasis. London; 2012 [cited 2014 Mar 
31]. Available from: http://guidance.nice.org.uk/cg153
c Sociedade Brasileira de Dermatologia. Consenso Brasileiro de Psoríase 2012: guias de avaliação e tratamento. 2. ed. Rio de Janeiro; 2012 
[cited 2014 Mar 31]. Available from: http://www.ufrgs.br/textecc/traducao/dermatologia/files/outros/Consenso_Psoriase_2012.pdf
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treatment should be continued with systemic medications 
(e.g., methotrexate, acitretin, and cyclosporine) before 
proceeding with the biological medications (e.g., etaner-
cept, infliximab, and adalimumab). The Protocolo Clínico 
e Diretrizes Terapêuticas (PCDT – Clinical Protocol and 
Therapeutic Guidelines) for the treatment of PSO in the 
Public Health System (SUS) was published in 2013.d The 
treatment excludes biological medications and follow-up 
includes clinical monitoring of the evolution of disease 
and analysis of adverse drug reactions. 
The access to biological medicines is achieved through 
the judicial system or via administrative means, which 
makes it difficult to plan and manage the expenses 
involved.2,6,16 The latter is implemented by some health 
departments to request medications that are not avail-
able at SUS but both generate a conflict regarding the 
principle of comprehensiveness proposed by SUS. 
The process that plaintiffs undergo to obtain access 
to biological medications is challenging, and the data 
pertaining to drug use, prescription, and effects (results 
and safety) are scarcely available. In addition, the docu-
mentation regarding the judicialization process is rarely 
disclosed in this type of study. Therefore, the purpose 
of our study was to analyze the access and utilization 
profile, obtained by judicial means, of biological medi-
cations for the treatment of PSO in Brazil.
METHODS
We performed a descriptive cross-sectional study with 
patients with PSO who were either undergoing treat-
ment or had been treated with biological medications 
by means of judicial actions against the state of Sao 
Paulo between 2004 and 2010.
The dispensation orders (DO) containing the biolog-
ical medication to be supplied per patient with PSO 
(International Classification of Diseases – ICD-L40), 
which was made available by the court control 
system of the Sao Paulo State Health Department 
(SCJ/SES-SP), provided an estimate of the population 
under treatment in the referred period. The following 
variables were collected: contested medication, author 
and type of action, and sociodemographic characteris-
tics of the plaintiff and prescriber. 
After locating corresponding records, we analyzed the 
documents presented to the court with information 
regarding the medical report, prescription, legal represen-
tation, type of injunction, appointed justice system, defen-
dant, civil or district court, and the origin of prescription. 
Patients who had retrieved and used biological medica-
tion during our study period and were willing to partici-
pate were included. They were found through injunctions 
filed against the state government, with a judicial decision 
in favor of the authors in any instance that were submitted 
to 14 public circuit courts of the capital of the State of Sao 
Paulo. We excluded patients who provided their contact as 
their lawyer’s office number, those who were not located 
after five attempts, and deceased patients.
Telephone contact was elected because it is effective 
and inexpensive.10 All interviews were performed using 
the computer-assisted telephone interviewing technique, 
with the use of a microcomputer coupled to a telephone 
device with a headset; specific management and recording 
software were connected simultaneously. This apparatus 
allows monitoring interviews, avoiding inconsistencies 
in the questionnaire and developing features related with 
research management such as automatic control of follow-
up calls, control of time per interview/interviewer, remote 
listening system, and real time control.
We developed a Microsoft Office Access® electronic 
form, based on the instrument used for the interviews 
with 16 screens to record the data. The language of the 
questionnaire was adapted for a telephone conversa-
tion. The team of interviewers was previously trained 
to standardize language and interview time.
The questionnaire included the following information: 
patient, type of medical assistance, access to medication 
for the treatment of PSO before the injunction, participa-
tion in a support group, meetings with the lawyer, contact 
with the pharmaceutical manufacturer, evolution of the 
disease, and use of medicine (time involved in diagnosis 
and treatment), provided pharmacotherapy follow-up, 
and suspected adverse drug reactions. This instrumente 
was previously validated by rheumatology and public 
health experts. The SCJ/SES-SP data, regarding injunc-
tions and interviews, were organized in an electronic 
spreadsheet. The data was analyzed with the 2013 version 
of Excel® software, and the results were shown as simple 
variable frequencies. The quality control of data collec-
tion was achieved by periodic crosschecking of informa-
tion, which was performed by one of the researchers who 
was not part of the on-the-spot data collection.
The prescriptions involved in the proceedings were analyzed 
in terms of legal provisions of the Law 5.991/1973.f
Data collection was authorized by the Health Department 
of Sao Paulo State. This study was approved by the 
Research Ethics Committee of the University of Sorocaba 
(Protocol 011/2009 of August 17, 2009), according to 
d Ministério da Saúde, Secretaria de Atenção à Saúde. Portaria nº 1.229, de 5 de novembro de 2013. Aprova o Protocolo Clínico e Diretrizes 
Terapêutica da Psoríase. Diario Oficial Uniao. 6 nov 2013;Seção 1:52.
e For those interested in the questionnaire, please contact the authors.
f Presidência da República. Lei nº 5.991, de 17 de dezembro de 1973. Dispõe sobre o Controle Sanitário do Comércio de Drogas, 
Medicamentos, Insumos Farmacêuticos e Correlatos, e dá outras Providências. Brasília (DF); 1973[cited 2014 Mar 31]. Available from: http://
www.planalto.gov.br/ccivil_03/leis/L5991.htm
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Resolution 196/96 of the National Health Council. All 
participants signed the informed consent form.
RESULTS
A total of 25,184 DO were analyzed regarding the 
lawsuits filed to obtain medication and other health 
products between 2004 and 2010. Of 218 identified 
patients, 11 did not meet the inclusion criterion and 
4 were excluded. Of 203 interviewed plaintiffs, 190 
processes were located (Figure). 
Adalimumab, etanercept, infliximab, and efalizumab 
were part of these DO. The sociodemographic charac-
teristics and the process toward access to a biological 
medicine are described in Table 1. A total of 44.9% 
patients used a biological medicine, of which 89.7% 
never requested the medicine to SUS before filing a 
lawsuit. Patients with access to private medical care 
(69.5%) were assisted by SUS (3.5%). Among SUS 
patients (30.5%), 12.9% were treated at University 
Hospitals (Hospital São Paulo, Puccamp, HU-USP, 
ABC Santo André University and Unicamp) (Table 1).
All patients treated with efalizumab (banned in Brazil 
since 2009) (n = 43) were not taking this medicine any 
longer when interviewed. Approximately 20.5% of the 
patients discontinued the use of biological medicines 
due to suspicion of adverse drug reactions which was 
confirmed by doctors. Adverse drug reactions included 
local reactions (70.0%), hospitalization after use of 
medicine, cardiovascular events (arrhythmia and high 
blood pressure), liver disease, blood dyscrasia, pneu-
monia, and kidney injury. The majority of patients 
discontinued using the biological medicine due to 
dropout (26.6%) or suspension by the physician 
(13.8%), which was caused by their worsening condi-
tion or lack of efficacy of medication (Table 2).
The highest request rate was for infliximab (57.4%), 
followed by efalizumab (21.6%), etanercept (16.3%), 
and adalimumab (4.7%). The Associação dos 
Portadores de Vitiligo e Psoríase do Estado de São 
Paulo (APVPESP – Association of Vitilligo and 
Psoriasis Patients of Sao Paulo State) provided legal 
representation to 12.6% patients (Table 3).
Of the 42 lawyers that represented the 203 plaintiffs 
in 90 lawsuits, three lawyers (7.1%; Group A) filed 88 
(46.3%) lawsuits; four lawyers (9.5%; Group B) filed 
42 lawsuits (22.1%); and 35 lawyers (83.3%; Groups 
C and D) filed between one and seven lawsuits each.
A total of 189 medical prescriptions attached to the 
lawsuits (n = 190) were analyzed. One lawsuit did not 
provide a prescription for the medicine etanercept. Legible 
names of patients were also absent in 5.3% of prescrip-
tions. Neither the generic name of the medicine nor the 
pharmaceutical dosage form were reported in 59.8% of 
cases, among other missing or incomplete information 
that are required by law, totaling 94.7% of cases (Table 4).
DISCUSSION
The majority of the analyzed lawsuits (n = 190) did not 
explicitly justify the prescription of a biological medicine 
or provide information regarding previous treatment, 
evolution of the disease, supplementary exams, or diag-
noses according to the ICD-10. Applicants used biolog-
ical medicines for periods of more than 13 months (4.0% 
of the patients have been using this medicine for > 49 
months), which extrapolates any follow-up of a high-
quality clinical study up to this date.8,14 As for medicine 
discontinuation, 11.3% of the patients were discontinued 
because of either suspicion of an adverse drug reaction 
or by their own or their physician’s decision, which was 
always related with worsening of the condition or lack of 
efficacy of the medicine. Ninety-one patients were still 
using a biological medicine when interviewed.
Patients (n = 203) were mostly male, age ranging from 
19 to 59 years, and residing in Sao Paulo. They acquired 
the medicine through an injunction, obtained in 7-10 
days (average time). They used the prerogative of 
free legal aid, despite having legal representation by a 
private lawyer and having been assisted in private care 
facilities. Three private lawyers represented patients in 
more than 40.0% of these lawsuits filed against the state. 
Instructions to obtain medicines via judicial process came 
from the medical doctors who assisted these patients 
(approximately three clinical practitioners prescribed 
80.0% of requested medicines). Approximately 60.0% of 
patients never had a meeting with their lawyers, having 
signed power of attorneys at the doctor’s office. In 20.0% 
of lawsuits, a Non-governmental organization (patient 
associations) was responsible for instructing patients to 
request a medicine through the courts. 
All patients visited their doctors once a year, but 70.3% of 
them visited for follow-up laboratory examinations (blood 
work, liver and kidney function tests), which would help 
them to detect possible adverse drug reactions.a
Whilst the use of biological medication for the treatment of 
moderate to severe PSO is considered a therapeutic break-
through with some short-term effectiveness and tolerance,a 
meta-analyses1,17 and field synopsesg advise caution in 
terms of long-term effectiveness and safety. National and 
international references3,15,a,c recommend these medicines 
as a third line of action, followed by careful monitoring 
for early identification of adverse drug reactions. 
g Naldi L, Rzany B. Psoriasis (chronic plaque). Clin Evid(Online). 2009[cited 2014 Mar 31];2009:1706. Available from: http://www.ncbi.nlm.
nih.gov/pmc/articles/PMC2907770/pdf/2009-1706.pdf
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Biological medications are administered via the IV route,9 
which can cause several local reactions, which were expe-
rienced by the patients in our study. Adverse drug reac-
tions differ from those caused by conventional chemical 
compounds because they are heterogeneous5,11,18 and may 
appear years after patients discontinue their use.4 Adverse 
drug reactions resulting from 1 year of use include malig-
nancies, opportunist infections caused by fungi, tubercu-
losis, hypertension, among others.13,14 Clinical monitoring 
of patient, as well as of the way to use the medication, 
duration of use, dose, and recommendations to patients 
are all essential ways to reduce and control these events.
The fact that the court granted petitions containing 
prescriptions lacking not only relevant legal requirements 
(almost 100% of this study) but also important data (name 
of patient, name of the prescribing practitioner registered 
in local Regional Medical Board, date, duration of treat-
ment, dose, generic name, among others), which are funda-
mental elements for proper prescribing and compulsory 
under current legislation, highlights the faulty drug use 
rationale evident in these petitions. Moreover, the situation 
exposes these plaintiffs to risks (disability, death) and also 
leads to other health issues (use of hospital beds, chronic 
treatments due to disability, among others) for the Health 
System, including direct and indirect costs. 
The (i) recommendations of the Comissão Nacional 
de Incorporação e Tecnologias (National Committee 
of Technology Incorporation) of SUS; (ii) Law 
12.401/2011h regarding therapeutic assistance and 
health technology incorporation in the scope of SUS; 
(iii) Decree 7.508/2011,i with provisions related to 
planning, health assistance, and joint federal actions; 
and (iv) the current PCDT,d do not recommend the use 
of these agents for the treatment of PSO. Brazilian 
physicians, even those working in SUS (30.5%) (Table 
1), do not comply with the official recommendations 
and prescribe these agents to patients with PSO. 
The supply of biological medicines used to treat 
PSO in the state of Sao Paulo is offered via registra-
tion of administrative requests in the Componente 
Especializado da Assistência Farmacêutica (CEAF 
– Specialized Pharmaceutical Care Program) but it 
does not require a proper clinical protocol follow-
up of patients. After the publication of Resolution 
SS-54, of May 11, 2012,j a Comissão de Farmacologia 
(Pharmacology Committee) was established in SES-SP 
to provide a computerized processing of administrative 
requests. It is the prescribing practitioner’s respon-
sibility to justify the need for a biological medicine. 
However, although the above measures have favored 
the management of requests and granted them a tech-
nical nature (based on scientific eligibility for the use 
of medicines), they have not lowered the number of 
lawsuits requesting biological medicines.
The majority of patients with PSO (69.5%) pursue a 
biological medicine through the public system, but their 
prescription is generated by a private system. Doctors’ 
visits and monitoring are performed at private facilities 
and medicines are supplied by the public system. Patient 
care is not comprehensive in any of the pathways, which 
does not comply with the principles of SUS.
h Presidência da República. Lei nº 12.401, de 28 de abril de 2011. Altera a Lei nº 8.080, de 19 de setembro de 1990, para dispor sobre a 
assistência terapêutica e a incorporação de tecnologia em saúde no âmbito do Sistema Único de Saúde - SUS. Brasília (DF); 2011 [cited 2014 
Mar 31]. Available from: http://www.planalto.gov.br/ccivil_03/_Ato2011-2014/2011/Lei/L12401.htm
i Presidência da República. Decreto nº 7.508, de 28 de junho de 2011. Regulamenta a Lei nº 8.080, de 19 de setembro de 1990, para dispor 
sobre a organização do Sistema Único de Saúde - SUS, o planejamento da saúde, a assistência à saúde e a articulação interfederativa, e dá outras 
providências. Brasília (DF); 2011 [cited 2014 Mar 31]. Available from: http://www.planalto.gov.br/ccivil_03/_ato2011-2014/2011/decreto/D7508.htm
j Secretaria de Estado da Saúde de São Paulo. Resolução SS-54, de 11 de maio de 2012. Aprova, no âmbito da Pasta, estrutura e 
funcionamento da Comissão de Farmacologia da Secretaria de Estado da Saúde de São Paulo, e dá outras providências. Diario Oficial Estado 
Sao Paulo. 12 maio 2012;Seção 1:37. [cited 2014 Mar 31]. Available from: www.adj.org.br/download/pdf/2012jur_resol54.pdf
Figure. Flowchart of the phases of sample composition. State of Sao Paulo, 2004-2010.
Interviewed patients (n = 203)
Patients who did not meet the inclusion
criterion (n = 11)
• Refusals (n = 9)
• Never retrieved the medicines (n = 2)
Excluded (n = 4)
• Lawyer’s office (n = 3)
• Deceased (n = 1)
Patients assessed for eligibility (N = 218)
Non-located lawsuits (n = 13)
Analyzed lawsuits (n = 190)
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Table 1. Sociodemographic characteristics and ways used to gain access to biological medicines to treat PSO by the authors 
of injunction filed against the state of Sao Paulo, 2004-2010.
Variable
Adalimumab Efalizumab Etanercept Infliximab Total
% n % n % n % n % n
6.8 14 21.2 43 17.3 35 54.7 111 100.0 203
Gender
Male 64.3 9 60.5 26 60.0 21 65.8 73 63.6 129
Female 35.7 5 38.6 17 40.0 14 34.2 38 36.4 74
City
Sao Paulo 85.7 12 46.5 20 71.4 25 58.6 65 60.1 122
Other locations 14.3 2 53.5 23 26.6 10 41.4 46 39.9 81
Age (years)
19 to 59 57.1 8 81.4 35 74.3 26 78.4 87 76.8 156
≥ 60 42.9 6 18.6 8 25.7 9 21.6 24 23.2 47
Type of medical assistance
Non-SUS 92.9 13 62.8 27 65.7 23 70.3 78 69.5 141
SUS 7.1 1 37.2 16 34.3 12 29.7 33 30.5 62
Registered at CEAF
Information provided by the patient (Yes) 42.9 6 65.1 28 40.0 14 51.4 57 51.7 105
Information confirmed in the system (Yes) 71.4 10 0.0 0 34.3 12 4.5 5 13.3 27
Patient was being treated by a biological medicinea 50.0 7 0.0 0 25.7 9 0.9 1 8.4 17
Guidance to obtain a biological medicine via lawsuit
Doctor 71.4 10 79.1 34 80.0 28 72.1 80 74.9 152
NGO, Family, and others 14.3 2 11.6 5 34.3 12 37.0 41 6.9 60
Lawyer 0.0 0 4.7 2 0.0 0 2.7 3 2.5 5
Pharmaceutical Laboratory 7.1 1 4.7 2 0.0 0 1.8 2 2.5 5
NI 7.1 1 0.0 0 0.0 0 0.9 1 1.0 2
Use of biological medicine before lawsuit
Yes 92.9 13 93.0 40 65.7 23 95.5 106 89.7 182
NI 0.0 0 0.0 0 0.0 0 3.6 4 2.0 4
Form of acquisition of medicine beforelawsuit
Pharmaceutical laboratory 7.1 1 6.8 3 14.3 5 0.0 0 4.4 9
Other (city hall, State, NGO) 0.0 0 0.0 0 8.6 3 0.9 1 2.0 4
Supplied by doctor 0.0 0 0.0 0 5.7 2 0.0 0 1.0 2
Own resources 0.0 0 0.0 0 2.9 1 0.0 0 0.5 1
NI 0.0 0 0.0 0 2.9 1 0.0 0 0.5 1
Request of medication for an institutionb before filing the lawsuit
No 92.9 13 95.3 41 77.1 27 84.7 94 86.2 175
NI 0.0 0 0.0 0 0.0 2 1.8 2 2.0 4
Institution activated for provision of medicine before lawsuit
Privatec 0.0 0 0.0 0 5.7 2 9.0 10 5.9 12
Public 7.1 1 2.3 1 17.1 6 2.7 3 5.4 11
NGO 0.0 0 2.3 1 0.0 0 0.0 0 1.5 1
Request fulfilled
Yes 7.1 1 0.0 0 2.9 1 1.8 2 1.5 3
Supply of biological medication by another institution (time in months)
< 6 0.0 0 0.0 0 0.0 0 1.8 2 0.5 2
> 6 7.1 1 0.0 0 2.9 1 0.0 0 0.5 1
Continue
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Continuation
Participation in a support group for patients
Yes 14.3 2 11.6 5 17.1 6 9.0 10 11.3 23
Number of meetings with the lawyer
None 64.3 9 58.1 25 62.9 22 62.2 69 61.6 125
One or more 35.7 5 34.9 15 34.3 12 37.9 42 36.5 74
NI 0.0 0 7.0 3 2.9 1 0.9 0 2.5 4
Contacted by the pharmaceutical laboratory
Yes 64.3 9 62.8 27 62.9 22 37.9 42 49.3 100
NI: not informed; SUS: Public Health System; NGO: Non-governmental organizations; CEAF: Specialized Pharmaceutical 
Care Program
a Patients who were receiving a biological medicine because they were registered at CEAF.
b Any public or private institution (City hall, NGO, laboratory, and others).
c Laboratory, private hospitals.
Table 2. Features of the pharmacotherapy follow-up provided to the plaintiff. Sao Paulo, SP, Southeastern Brazil, 2004-2010.
Variable
Adalimumab Efalizumab Etanercept Infliximab Total
% n % n % n % n % n
6.8 14 21.2 43 17.3 35 54.7 111 100.0 203
Diagnosis time
≥ 6 years 85.7 12 90.7 39 85.7 30 86.5 96 87.2 177
2 to 5 years 14.3 2 9.3 4 14.3 5 12.6 14 12.3 25 
Up till 6 months 0.0 0 0.0 0 0.0 0 0.9 1 0.5 1
Concurrent disease 
Yes 50.0 7 51.1 22 37.1 13 29.8 33 37.0 75
Treatment time with biological medicine (months) 
Up to 12 35.7 5 51.2 22 22.9 8 30.6 34 34.0 69
13 to 48 35.7 5 48.9 21 74.3 26 66.7 74 62.0 126
49 to 72 28.6 4 0.0 0 2.9 1 2.7 3 4.0 8
Average (SD) 31.4 (22.2) 16.8 (10.2) 26.4 (14.4) 25.2 (14.6) 24.0 (14.9)
Patient was using obtained biological medicine
Yes 64.3 9 0.0 0 62.9 22 54.0 60 44.9 91
Clinical monitoringa
Medical visit 100.0 9 0.0 0 100.0 22 100.0 60 100.0 91
Laboratory exams 55.5 5 0.0 0 68.2 15 73.3 44 70.3 64
Reasons to discontinue the use of biological medicine
Stopped usingb 0.0 0 100 43 5.7 2 8.1 9 26.6 54
Suspension by the doctor 14.3 2 0.0 0 22.9 8 16.2 18 13.8 28
Suspicion of ADR 21.4 3 0.0 0 5.7 2 16.2 18 11.3 23
Suspended by a court decision 0.0 0 0.0 0 2.9 1 6.4 6 34.5 7
Perception of the efficacy of the biological medicine
Yes 71.4 10 76.2 32 91.4 32 82.0 91 81.3 165
No 28.6 4 21.0 9 8.6 3 17.1 19 17.2 35
NI 0.0 0 4.7 2 0.0 0 0.9 1 2.7 3
Perception of the evolution of the disease with the use of biological medicines
Improved/Cured 57.1 8 60.5 26 71.4 25 67.6 75 66.0 134
Stationary 28.6 4 23.3 10 20.0 7 21.7 24 22.2 45
Worsened 14.3 2 11.7 5 2.9 1 10.9 12 9.9 20
NI 0.0 0 4.7 2 5.7 2 0.0 0 2.0 4
NI: not informed; ADR: adverse drug reactions, SD: standard deviation
a According to recommendations of therapeutic guidelines.
b Other reasons.
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Table 3. Technical characteristics of injunctions filed against the state of Sao Paulo, 2004-2010.
Variable
Adalimumab Efalizumab Etanercept Infliximab Total
% n % n % n % n % n
4.7 9 21.6 41 16.3 31 57.4 109 100.0 190
Number of authors per injunction
1 11.1 1 95.1 39 93.5 29 100.0 109 93.7 178
2 to 6 88.9 8 4.9 2 6.5 2 0.0 0 6.3 12
Type of injunction
CI 88.9 8 48.8 20 58.1 18 61.5 67 59.5 113
RO 11.1 1 51.2 21 41.9 13 37.5 41 40.0 76
Public Defender 0.0 0 0.0 0 0.0 0 0.9 1 0.5 1
Civil Society Representation
No 100.0 9 51.2 21 96.8 30 92.7 101 84.7 161
Yes 0.0 0 48.8 20 3.2 1 7.3 8 15.3 29
Defendant
State 88.9 8 100.0 41 100.0 31 100.0 109 99.5 189
Union 11.1 1 0.0 0 0.0 0 0.0 0 0.5 1
Judicial Representation
Private 100.0 9 48.8 20 96.8 30 92.7 101 84.2 160
APVPESP 0.0 0 48.8 20 3.4 1 2.8 3 12.6 24
MP 0.0 0 2.4 1 0.0 0 1.8 2 1.6 3
PD 0.0 0 0.0 0 0.0 0 2.8 3 1.6 3
Free Legal Aid
Yes 56.6 5 75.6 31 64.5 20 75.2 82 72.6 138
No 11.1 1 12.2 5 9.7 3 16.5 18 14.2 27
NI 33.3 3 12.2 5 25.8 8 8.3 9 13.2 25
Primary injunction
Yes 88.9 8 53.7 22 61.3 19 56.0 61 57.9 110
No 11.1 1 31.7 13 25.8 8 24.4 32 28.4 54
NI 0.0 0 14.6 6 12.9 4 14.7 16 13.7 26
District injunction /Civil injunction of Sao Paulo/Osasco
1 to 5 55.6 5 43.9 18 35.5 11 30.3 33 35.3 67
6 to 10 44.4 4 29.3 12 41.9 13 46.8 51 42.1 80
11 to 14 0.0 0 26.8 11 22.6 7 21.1 23 21.6 41
Osasco (1 to 2) 0.0 0 0.0 0 0.0 0 1.8 2 1.1 2
Legal representation of author(s) – OAB
A 88.9 8 48.8 20 0.0 0 55.0 60 46.3 88
B 11.1 1 4.9 2 35.5 11 25.7 28 22.1 42
C 0.0 0 39.0 16 22.6 7 4.6 5 14.7 28
D 0.0 0 2.4 1 41.9 13 11.9 13 14.2 27
PD 0.0 0 2.4 1 0.0 0 2.8 3 2.1 4
NI 0.0 0 2.4 1 0.0 0 0.0 0 0.5 1
CI: court injunction; RO: ordinary proceedings; PD: Public Defender; MP: Public Prosecutor’s Office or Public Ministry; 
APVPESP: Association of Vitilligo and Psoriasis of the state of Sao Paulo; NI: not informed; OAB: Brazilian Bar Association; 
A: three lawyers had between 21 and 35 representations; B: four lawyers had between 10 and 13 representations; C: 12 
lawyers had between two and seven representations; D: 22 lawyers had at least one representation per medicine
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The pharmaceutical manufacturers maintained frequent 
contact with more than 50.0% of patients. This suggests 
possible influence on patients’ needs, transforming them 
into legal demands.
The legal request of medicines without scientific evidence 
weakens pharmaceutical services because it exposes the 
patient to risks and promotes the financing of technologies 
devoid of proper proof of efficacy and safety.6,8 Efalizumab 
was approved for the treatment of PSO in the USA and 
Europe in 2003. Its marketing was suspended due to 
safety concerns in 2009 (three cases of progressive multi-
focal leukoencephalopathy), in addition to efficacy issues, 
rending it inferior to other biological medicines.5 Then, 
the access to this drug was obtained via lawsuits in Brazil. 
Table 4. Medical prescriptions linked to lawsuits, according to legal precepts(Law 5.991/1973).a Sao Paulo, SP, Southeastern 
Brazil, 2004-2010.
Variable
Adalimumab Efalizumab Etanercept Infliximab Total
% n % n % n % n % n
4.8 9 21.7 41 15.9 30 57.7 109 100.0 189
Legible name of author (patient)
No 0.0 0 2.4 1 6.7 2 6.4 7 5.3 10
Author’s address (patient)
No 100.0 9 100.0 41 100.0 30 100.0 109 100.0 189
Generic name 
No 77.8 7 39.0 16 66.7 20 64.2 70 59.8 113
Trade name
No 22.2 2 0.0 0 23.3 7 21.1 23 16.9 32
Pharmaceutical form
No 88.9 8 100.0 41 86.7 26 95.4 104 94.7 179
Concentration
No 44.4 4 58.5 24 13.3 4 19.3 21 28.0 53
Administration route
No 11.1 1 12.2 5 13.3 4 20.2 22 16.9 32
Dosage
No 11.1 1 53.7 22 66.7 20 56.0 61 55.0 104
Duration of treatment
No 77.8 7 85.4 35 90.0 27 89.9 98 88.4 167
Interval between doses
No 11.1 1 7.3 3 16.7 5 13.8 15 12.7 24
Total quantity
No 77.8 7 85.4 35 90.0 27 89.9 98 88.4 167
Name of the Doctor
No 0.0 0 2.4 1 3.3 1 3.7 4 3.2 6
CRM
No 0.0 0 0.0 0 0.0 0 0.9 1 0.5 1
Illegible 0.0 0 7.3 3 16.7 5 11.9 13 11.1 21
Address of prescribing practitioner’s medical institution
No 0.0 0 4.9 2 3.3 1 10.1 11 7.4 14
Date
No 0.0 0 4.9 2 0.0 0 11.0 12 7.4 14
Illegible 0.0 0 0.0 0 0.0 0 0.9 1 0.5 1
Source: lawsuits. Coordination of Strategic Demands of SUS (Codes). Health Department of Sao Paulo State. 
CRM: Conselho Regional de Medicina (Regional Council of Medicine)
a Presidência da República. Lei nº 5.991, de 17 de dezembro de 1973. Dispõe sobre o Controle Sanitário do Comércio de 
Drogas, Medicamentos, Insumos Farmacêuticos e Correlatos, e dá outras Providências. Brasília (DF); 1973 [cited 2014 Mar 
31]. Available from: http://www.planalto.gov.br/ccivil_03/leis/L5991.htm
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Approximately 21.2% of patients in our study gained access 
to efalizumab via lawsuits deferred by the state of Sao Paulo. 
Most of the interviewees were diagnosed more than six 
years ago. Some of the data may have suffered from 
recall bias. Patients who are still being treated with a 
biological medicine have been receiving it for more 
than 24 months. On the other hand, most of the data 
was crosschecked with the SES-SP database and with 
the clinical lab results provided by the patients them-
selves during interviews. The utilization data of biolog-
ical medications were confirmed by the pharmacy from 
which each of the patients received these medicines.
Considering the limitations of any observational study, 
the results of this study may play an important role in the 
process of decision making in Public Health in Brazil. 
To the best of our knowledge, this is the first set of data 
on the use of biological medicines by patients with PSO 
financed by judicial demands in Brazil. This is impor-
tant information for dermatologists, because it provides 
a real-life view of clinical practice, a goal that is hard 
to achieve with randomized controlled clinical trials. 
Some treatments are associated with potentially serious 
adverse drug reactions. Therefore, in the long-term 
observational studies may provide additional and impor-
tant information for doctors, users, manufacturers and 
researchers to assess the risks and benefits of treatments.
To perceive the public health system as one that may 
provide services without the requirements of in-place 
regulation, planning, forecasting of financial resources 
or epidemiological background is imprudent and can 
collapse the system.
The plaintiffs selected the judicial procedures to obtain 
biological medicines because they are either unaware of 
other routes or find difficulty in accessing the institutional 
pathways of SUS. Easy access provided by courts favors 
the use of biological medicines for an extended period of 
time through irregular prescriptions, the high frequency 
of adverse drug reactions and inappropriate clinical moni-
toring. Strict compliance to PCDT may guarantee access, 
effectiveness, and safety of an appropriate therapy for PSO.
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This study aimed to analyze the legal access to and usage profile of biological drugs for the treatment of psoriasis. 
The legal access to medications distorts planning and spending and undermines the principle of a comprehensive 
health care system proposed by the Brazilian Unified Health System (SUS). 
A total of 203 applicants were interviewed, and 190 patients requiring biological drugs for psoriasis (adalimu-
mab, efalizumab, etanercept, and infliximab) were examined. The patients obtained the drugs through a writ of 
mandamus (59.5%); without the need to request the drugs from another institution, either private or through SUS 
(86.2%); and using the prerogative of gratuity justice (72.6%). However, 91.1% of the patients were represented 
by a private attorney, 69.5% received assistance in private medical offices, and 60.0% had never met with their 
attorneys and therefore needed to sign proxies at the doctor’s office.
In addition, 20.5% of the patients discontinued the use of biological drugs because they reported suspected adverse 
reactions previously confirmed by doctors – reactions at the application site, hospitalization after medication use, 
cardiovascular events (arrhythmia, hypertension), liver disease, blood dyscrasia, pneumonia, renal injury, etc. Most 
patients discontinued the use of these drugs on their own (26.6%) or following doctor’s recommendation (13.8%) 
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